Tonix Pharmaceuticals Holding Corp. (TNXP) stock
TNXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3084% below fair value
$3.01−0.23 (-7.10%)
Close on Nov 13, 2026Market cap $51.62MP/E –Yield –
Tonix Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Tonix Pharmaceuticals's ebitda for the twelve months ending Sep 30, 2026 was -$185.55M. For fiscal 2025 it was -$123.78M. The highest annual figure on record is -$10.87M in fiscal 2013.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$123.78M | – |
| FY2024 | Dec 31, 2024 | -$133.28M | – |
| FY2023 | Dec 31, 2023 | -$114.09M | – |
| FY2022 | Dec 31, 2022 | -$110.84M | – |
| FY2021 | Dec 31, 2021 | -$92.26M | – |
| FY2020 | Dec 31, 2020 | -$50.48M | – |
| FY2019 | Dec 31, 2019 | -$28.80M | – |
| FY2018 | Dec 31, 2018 | -$26.27M | – |
| FY2017 | Dec 31, 2017 | -$21.22M | – |
| FY2016 | Dec 31, 2016 | -$38.76M | – |
| FY2015 | Dec 31, 2015 | -$48.00M | – |
| FY2014 | Dec 31, 2014 | -$27.62M | – |
| FY2013 | Dec 31, 2013 | -$10.87M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$54.83M | – |
| Q2 FY2026 | Jun 30, 2026 | -$41.94M | – |
| Q1 FY2026 | Mar 31, 2026 | -$40.98M | – |
| Q4 FY2025 | Dec 31, 2025 | -$47.80M | – |
| Q3 FY2025 | Sep 30, 2025 | -$32.67M | – |
| Q2 FY2025 | Jun 30, 2025 | -$27.80M | – |
| Q1 FY2025 | Mar 31, 2025 | -$15.56M | – |
| Q4 FY2024 | Dec 31, 2024 | -$21.98M | – |
| Q3 FY2024 | Sep 30, 2024 | -$15.05M | – |
| Q2 FY2024 | Jun 30, 2024 | -$76.42M | – |
| Q1 FY2024 | Mar 31, 2024 | -$20.14M | – |
| Q4 FY2023 | Dec 31, 2023 | -$26.07M | – |
| Q3 FY2023 | Sep 30, 2023 | -$27.15M | – |
| Q2 FY2023 | Jun 30, 2023 | -$28.10M | – |
| Q1 FY2023 | Mar 31, 2023 | -$33.01M | – |
| Q4 FY2022 | Dec 31, 2022 | -$31.89M | – |
| Q3 FY2022 | Sep 30, 2022 | -$29.34M | – |
| Q2 FY2022 | Jun 30, 2022 | -$23.23M | – |
| Q1 FY2022 | Mar 31, 2022 | -$26.37M | – |
| Q4 FY2021 | Dec 31, 2021 | -$29.45M | – |
| Q3 FY2021 | Sep 30, 2021 | -$18.53M | – |
| Q2 FY2021 | Jun 30, 2021 | -$23.56M | – |
| Q1 FY2021 | Mar 31, 2021 | -$20.73M | – |
| Q4 FY2020 | Dec 31, 2020 | -$17.02M | – |
| Q3 FY2020 | Sep 30, 2020 | -$11.99M | – |
| Q2 FY2020 | Jun 30, 2020 | -$14.19M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.29M | – |
| Q4 FY2019 | Dec 31, 2019 | -$8.73M | – |
| Q3 FY2019 | Sep 30, 2019 | -$7.89M | – |
| Q2 FY2019 | Jun 30, 2019 | -$5.90M | – |
| Q1 FY2019 | Mar 31, 2019 | -$6.29M | – |
| Q4 FY2018 | Dec 31, 2018 | -$7.64M | – |
| Q3 FY2018 | Sep 30, 2018 | -$5.53M | – |
| Q2 FY2018 | Jun 30, 2018 | -$6.13M | – |
| Q1 FY2018 | Mar 31, 2018 | -$6.97M | – |
| Q4 FY2017 | Dec 31, 2017 | -$5.52M | – |
| Q3 FY2017 | Sep 30, 2017 | -$5.82M | – |
| Q2 FY2017 | Jun 30, 2017 | -$4.81M | – |
| Q1 FY2017 | Mar 31, 2017 | -$5.07M | – |
| Q4 FY2016 | Dec 31, 2016 | -$7.47M | – |
See a number that looks wrong?